TY - JOUR
T1 - Racemases and epimerases operating through a 1,1-proton transfer mechanism
T2 - Reactivity, mechanism and inhibition
AU - Lloyd, Matthew D.
AU - Yevglevskis, Maksims
AU - Nathubhai, Amit
AU - James, Tony D.
AU - Threadgill, Michael D.
AU - Woodman, Timothy J.
N1 - Funding Information:
The authors have been funded by Prostate Cancer UK (grants S10-03 and PG14-009), LifeArc, Biochemical Society Summer Vacation Studentships, the Cancer Research @ Bath network and a Bath-Shandong Undergraduate Exchange Studentship. TDJ wishes to thank the Royal Society for a Wolfson Research Merit Award and the Open Research Fund of the School of Chemistry and Chemical Engineering, Henan Normal University for support (2020ZD01). Diagrams in Schemes 9B and C have been reproduced from Yevglevskis et al., 2017127 with permission from the Royal Society of Chemistry.
Publisher Copyright:
© The Royal Society of Chemistry.
PY - 2021/5/24
Y1 - 2021/5/24
N2 - Racemases and epimerases catalyse changes in the stereochemical configurations of chiral centres and are of interest as model enzymes and as biotechnological tools. They also occupy pivotal positions within metabolic pathways and, hence, many of them are important drug targets. This review summarises the catalytic mechanisms of PLP-dependent, enolase family and cofactor-independent racemases and epimerases operating by a deprotonation/reprotonation (1,1-proton transfer) mechanism and methods for measuring their catalytic activity. Strategies for inhibiting these enzymes are reviewed, as are specific examples of inhibitors. Rational design of inhibitors based on substrates has been extensively explored but there is considerable scope for development of transition-state mimics and covalent inhibitors and for the identification of inhibitors by high-throughput, fragment and virtual screening approaches. The increasing availability of enzyme structures obtained using X-ray crystallography will facilitate development of inhibitors by rational design and fragment screening, whilst protein models will facilitate development of transition-state mimics.
AB - Racemases and epimerases catalyse changes in the stereochemical configurations of chiral centres and are of interest as model enzymes and as biotechnological tools. They also occupy pivotal positions within metabolic pathways and, hence, many of them are important drug targets. This review summarises the catalytic mechanisms of PLP-dependent, enolase family and cofactor-independent racemases and epimerases operating by a deprotonation/reprotonation (1,1-proton transfer) mechanism and methods for measuring their catalytic activity. Strategies for inhibiting these enzymes are reviewed, as are specific examples of inhibitors. Rational design of inhibitors based on substrates has been extensively explored but there is considerable scope for development of transition-state mimics and covalent inhibitors and for the identification of inhibitors by high-throughput, fragment and virtual screening approaches. The increasing availability of enzyme structures obtained using X-ray crystallography will facilitate development of inhibitors by rational design and fragment screening, whilst protein models will facilitate development of transition-state mimics.
KW - Allosteric Regulation
KW - Biocatalysis
KW - Catalytic Domain
KW - Coenzymes/metabolism
KW - Drug Design
KW - Enzyme Inhibitors/chemistry
KW - Molecular Dynamics Simulation
KW - Protons
KW - Racemases and Epimerases/antagonists & inhibitors
KW - Substrate Specificity
UR - http://www.scopus.com/inward/record.url?scp=85106563726&partnerID=8YFLogxK
U2 - 10.1039/d0cs00540a
DO - 10.1039/d0cs00540a
M3 - Review Article
C2 - 34027955
AN - SCOPUS:85106563726
SN - 0306-0012
VL - 50
SP - 5952
EP - 5984
JO - Chemical Society Reviews
JF - Chemical Society Reviews
IS - 10
ER -